Management of early-stage HER2-positive breast cancer and attitudes towards HER2DX test in Spain: insights from a nationwide survey

CONCLUSION: In the context of early-stage HER2+ breast cancer in Spain, a notable diversity in therapeutic approaches was observed. The majority of interviewed medical oncologists acknowledged HER2DX as a clinically valuable test for specific patients, in line with the 2022 SEOM-GEICAM-SOLTI clinical guidelines for early-stage breast cancer. To facilitate the full integration of HER2DX into clinical guidelines, conducting prospective studies to further validate its efficacy and utility was recommended.PMID:38653928 | DOI:10.1007/s12094-024-03409-4

Source: Clinical Breast Cancer - April 23, 2024 Category: Cancer & Oncology Authors: Olga Mart ínez-Sáez Javier Cort és Eva Ciruelos Mercedes Mar ín-Aguilera Gloria Gonz ález Laia Par é Adriana Herrera Patricia Villagrasa-Gonz ález Aleix Prat Miguel Mart ín Source Type: research